Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Left ventricular non-compaction (LVNC) is a heterogeneous myocardial disorder characterized by prominent trabeculae protruding into the left ventricular lumen and deep intertrabecular recesses. LVNC can manifest in isolation or alongside other heart muscle diseases. Its occurrence among children is rising due to advancements in imaging techniques. The origins of LVNC are diverse, involving both genetic and acquired forms. The clinical manifestation varies greatly, with some cases presenting no symptoms, while others typically manifesting with heart failure, systemic embolism, and arrhythmias. Diagnosis mainly relies on assessing heart structure using imaging tools like echocardiography and cardiac magnetic resonance. However, the absence of a universally agreed-upon standard and limitations in diagnostic criteria have led to ongoing debates in the scientific community regarding the most reliable methods. Further research is crucial to enhance the diagnosis of LVNC, particularly in early life stages.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871098 | PMC |
| http://dx.doi.org/10.3390/diagnostics14010115 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Circulating metabolites in patients with chronic heart failure are not related to gut leakage or gut dysbiosis.
PLoS One
September 2025
Department of Cardiology Ullevaal, Oslo University Hospital, Oslo, Norway.
Background: The gut microbiota produces numerous metabolites that can enter the circulation and exert effects outside the gut. Several studies have reported altered gut microbiota composition and circulating metabolites in patients with chronic heart failure (HF) compared to healthy controls. Limited data is available on the interplay between dysbiotic features of the gut microbiota and altered circulating metabolites in HF patients.
View Article and Find Full Text PDFEchocardiographic findings in young adults with primary hypertension: A scoping review protocol.
PLoS One
September 2025
Centre for Diagnostic, Therapeutic and Investigative Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Echocardiography is the primary imaging tool for evaluating cardiac structure and function in patients with primary hypertension. A significant limitation of the current literature is that most studies focus on older adults, leaving a significant gap in understanding the cardiac effects of primary hypertension in young adults. This scoping review protocol aims to assess conventional echocardiographic parameters, left ventricular geometric patterns, and advanced echocardiographic findings for the early detection of cardiac changes in young adults aged 18-39 with primary hypertension.
View Article and Find Full Text PDFTerminal Harvest Procedure of a Large Animal Model of Chronic Myocardial Ischemia with Hemodynamic Characterization and Perfusion Analysis.
J Vis Exp
August 2025
Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert Medical School, Brown University; Cardiovascular Research Center, Rhode Island Hospital.
Reproducibility and research integrity are foundational tenets to scientific discovery, which are produced utilizing well-established, proven principles and protocols. Furthermore, with the ever-increasing prevalence and burden cardiovascular disease (CVD) places on individuals and society at large, it deems essential to cultivate robust and validated model for investigation. Our group utilizes a two-surgery protocol in a swine model that has been progressively refined over the last twenty years, in which we first induce chronic myocardial ischemia by placement of an ameroid constrictor mimicking the pathophysiology of coronary artery disease (CAD) in humans.
View Article and Find Full Text PDFBackground: At present, existing risk scores together with traditional biomarkers such as troponin and brain natriuretic peptide (BNP) are still unable to accurately predict cancer therapy-related cardiac dysfunction (CTRCD). MicroRNAs (miRNAs) have emerged as promising biomarkers for improved identification of high-risk patients; however, limited studies have been performed in patients with HER2-positive breast cancer.
Objectives: To investigate the predictive potential of six serum-derived circulating miRNAs for CTRCD occurrence in patients with early-stage HER2-positive breast cancer receiving trastuzumab (TTZ).
A novel treatment score (QUAD score) to promote treatment optimization in heart failure with a reduced ejection fraction.
ESC Heart Fail
September 2025
School of Cardiovascular and Metabolic Health, University of Glasgow, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow, UK.
Aims: To help avoid therapeutic inertia, we developed a pragmatic treatment score (QUAD Score) for use in daily practice by healthcare professionals managing patients with a left ventricular ejection fraction (LVEF) < 50% and heart failure. We now investigate the association between achieved QUAD scores and 1 year outcomes.
Methods: This was a multicentre cohort study in consecutive patients with incident heart failure and LVEF <50%, who completed therapy titration between January 2021 and June 2023.